Skip to main
ESLA

ESLA Earnings Dates & Reports

ESLA Most Recent Earnings

Report Date
Period EndingQ4 2025
Est. EPS-$0.12
Actual EPS-$0.01
EarningsBeat

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

ESLA Earnings per Share (EPS) History

Signup for full access
Browse free

ESLA Latest Earnings

The value each ESLA share was expected to gain vs. the value each share gained.

ESLA reported its most recent earnings on for Q4 2025, posting earnings per share (EPS) of -$0.01. This exceeded analysts' expectations of -$0.12 by 91.67%, marking a Beat.

For comparison, Estrella Immunopharma Inc reported EPS of -$0.13 in the same quarter last year.

The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$0.12.

ESLA Earnings History

Earnings
Est. EPSActual EPSSurprise
Q1 2026
-$0.12
Q4 2025
-$0.12-$0.01-91.67%
Q3 2025
-$0.13
Q2 2025
-$0.11-$0.15+36.36%
Q1 2025
-$0.06
View all

ESLA Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the Estrella Immunopharma Inc’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange

ESLA Earnings FAQs

ESLA last reported earnings on Mar 18, 2026 for Q4 2025, posting an EPS of -$0.01, which Beat the estimate of -$0.12 by 91.67%.

For Q4 2025, ESLA reported an EPS of -$0.01, exceeding analysts' estimate of -$0.12 by 91.67%.

For Q4 2025, ESLA Beat expectations with an actual EPS of -$0.01 vs. an estimated EPS of -$0.12.

Following the last earnings report on Mar 18, 2026, ESLA's stock price moved — from — to —.

The next ESLA earnings call is scheduled for May. 26, 2026, where executives will discuss financial results and outlook.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.